FDA’s Chief Drug Regulator George Tidmarsh Resigns Amid Investigation
George Tidmarsh, the chief drug regulator at the Food and Drug Administration (FDA), has resigned amid an investigation into his actions. This decision comes after allegations that he misused his authority to cause financial harm to a former business associate.
Investigation Details
The investigation was initiated by FDA Commissioner Marty Makary following a complaint from Kevin Tang, a health care investor based in San Diego. Makary placed Tidmarsh on administrative leave as the inquiry unfolded. Tang has accused Tidmarsh of harboring a “longstanding personal vendetta” against him.
Legal Actions
Tang’s affiliated company, Aurinia Pharmaceuticals, filed a lawsuit against Tidmarsh, intensifying the scrutiny on his conduct. Tidmarsh confirmed that he learned of his administrative leave when he was unexpectedly locked out of his agency email account.
Response and Resignation
Despite facing serious allegations, Tidmarsh maintains his innocence. A representative from the Department of Health and Human Services, which oversees the FDA, stated that Tidmarsh’s resignation was effective immediately, occurring on Sunday morning.
Implications for the FDA
George Tidmarsh’s resignation raises concerns about the leadership within the FDA’s regulatory framework, particularly in its Center for Drug Evaluation and Research. As this situation develops, the FDA will likely face scrutiny regarding its internal controls and oversight mechanisms.
- Name: George Tidmarsh
- Position: Chief Drug Regulator, FDA
- Allegations: Misuse of authority against Kevin Tang
- Legal Action: Lawsuit by Aurinia Pharmaceuticals
- Commissioner: Marty Makary
- Status: Resigned effective immediately
